Tivic Health (TIVC) announced it has received, from Statera Biopharma (STAB), two investigational new drug applications for its lead candidate, Entolimod. The two INDs cover the use of Entolimod to treat acute radiation syndrome, including both hematopoietic and gastrointestinal sub-syndromes, and the use of Entolimod to treat advanced cancers, including as an anti-tumor agent and for conditions resulting from cancer treatments.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TIVC:
- Tivic Health Shifts Focus to Biopharmaceuticals
- Tivic Health Systems Shifts Focus to Biopharmaceuticals
- Tivic Health files to sell 400,044 shares of common stock for holders
- Tivic Health files to sell 605,023 shares of common stock for holders
- Tivic appoints Lisa Wolf permanent CFO, Chief Scientific Officer to step down